FAM83A: A Prognostic Biomarker and Its Correlation with Immune Infiltration in Lung Adenocarcinoma

Abstract Background: FAM83A (Family with sequence similarity 83, member A) has been found to promote tumor cell proliferation and accelerate the progression of several cancer types. However, integrated studies on the prognostic value of FAM83A and its function as an immunotherapy target in pan-cancers remain limited.Methods: Multiple online databases, including ONCOMINE, PrognoScan, Kaplan-Meier plotter, GEPIA, Lung Cancer Explorer, and TIMER, were accessed to evaluate the clinical prognostic value of FAM83A and its association with tumor-infiltrating immune cells across different cancer types.Results: Compared with normal tissues, the expression of FAM83A was higher in breast, colorectal, gastric, head and neck, and lung cancers. High FAM83A expression significantly correlated with inferior overall survival (OS) in lung cancer including lung adenocarcinoma (LUAD). In patients with LUAD, overexpressed FAM83A was negatively associated with infiltration levels of B cells and dendritic cells. In addition, the FAM83A expression level was positively associated with PD-L1, STAT1, STAT3, and JAK1 in LUAD.Conclusions: The high expression level of FAM83A was significantly correlated with a worse prognosis, which was also associated with a decreased level of infiltration of B cells and dendritic cells. FAM83A might increase the expression of PD-L1 through JAK / STAT pathway in the tumor microenvironment of lung adenocarcinoma.